Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study

Read full text Summarise with VIRAT
Authors: Jung Yeon Lee, Suein Choi, Seungpil Jung, Sung‐Soo Park, Jin Seok Kim, Seung‐Hwan Shin, Young‐Woo Jeon, Seung‐Ah Yahng, Je-Jung Lee, Hyo Jung Kim, Gyeong-Won Lee, Hyeon‐Seok Eom
+5 more Min Kyoung Kim, Yundeok Kim, Jihyun Kwon, Chang‐Ki Min, Korean Multiple Myeloma Working Party
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bortezomib-melphalan-prednisone (VMP) is an established induction regimen for transplant-ineligible newly diagnosed multiple myeloma (NDMM), yet optimal post-induction strategies remain unclear. This study evaluated the effectiveness of bortezomib maintenance following VMP using target trial emulation. We compared a prospective maintenance cohort (KMMWP-174 study) with an external control cohort from a multicenter registry. Eligible patients completed 9 VMP cycles, achieved ≥ partial response, and were progression-free for 60 days. The index date was maintenance initiation for cases and day 60 post-VMP for controls. Propensity score matching (1:1) balanced baseline covariates. The primary endpoint was progression-free survival (PFS); overall survival (OS) was secondary. Sensitivity analyses included multivariable regression, landmark analyses, and E-value assessment. Among 178 eligible patients, 60 comprised the maintenance cohort and 118 the control cohort; 54 per group were analyzed after matching. Median PFS was significantly longer with bortezomib maintenance (26.5 vs. 8.8 months; HR 0.437, 95% CI: 0.275–0.694, P < 0.001). PFS benefits were consistent across subgroups, including patients aged ≥ 70 years, those with ISS stage II-III disease, and those with high-risk cytogenetics. OS showed a favorable trend (HR 0.703, P = 0.252). Grade ≥ 3 adverse events occurred in 31.4% (control) and 18.7% (maintenance). No grade ≥ 3 peripheral neuropathy was observed. Bortezomib maintenance following VMP significantly prolonged PFS in transplant-ineligible NDMM with acceptable toxicity. These real-world data support proteasome inhibitor-based maintenance where VMP remains widely used, particularly among older adults with limited treatment options.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Bone health and treatments Multiple Sclerosis Research Studies

Publication details

Journal / source
Annals of Hematology
Volume
105
Issue
4
Publication date
23 March 2026
Language
EN